Variable | Categories | Pre-RT pain1 (N = 349) | Post-RT pain1 (N = 335) | RT-related pain2 (N = 262) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No (< 4) | Yes (≥ 4) |  | No (< 4) | Yes (≥ 4) |  | No | Yes |  | ||||||||
N | % | N | % | P 3 | N | % | N | % | P 3 | N | % | N | % | P 3 | ||
Total | Â | 290 | 83 | 59 | 17 | Â | 233 | 70 | 102 | 30 | Â | 203 | 77 | 59 | 23 | Â |
Race/ethnicity | NHW | 53 | 96 | 2 | 4 | 0.016 | 45 | 88 | 6 | 12 | 0.003 | 42 | 89 | 5 | 11 | 0.018 |
AA | 58 | 82 | 13 | 18 | Â | 42 | 60 | 28 | 40 | Â | 37 | 66 | 19 | 34 | Â | |
HW | 179 | 80 | 44 | 20 | Â | 146 | 68 | 68 | 32 | Â | 124 | 78 | 35 | 22 | Â | |
Age (years) | < 50 | 75 | 81 | 17 | 19 | 0.639 | 51 | 60 | 34 | 40 | 0.027 | 46 | 69 | 21 | 31 | 0.045 |
≥ 50 | 215 | 84 | 42 | 16 |  | 182 | 73 | 68 | 27 |  | 157 | 81 | 38 | 19 |  | |
BMI (kg/m2) | < 25 | 84 | 88 | 11 | 12 | 0.009 | 68 | 81 | 16 | 19 | 0.001 | 63 | 85 | 11 | 15 | 0.075 |
25–29.99 | 101 | 88 | 14 | 12 |  | 85 | 74 | 30 | 26 |  | 73 | 78 | 20 | 22 |  | |
≥ 30 | 105 | 75 | 34 | 25 |  | 80 | 59 | 56 | 41 |  | 67 | 71 | 28 | 29 |  | |
Sum of 12 comorbid conditions4 | 0 | 114 | 84 | 22 | 16 | 0.897 | 103 | 75 | 34 | 25 | 0.009 | 87 | 83 | 18 | 17 | 0.009 |
1 | 111 | 83 | 22 | 17 | Â | 88 | 73 | 33 | 27 | Â | 79 | 81 | 18 | 19 | Â | |
2 | 48 | 83 | 10 | 17 | Â | 32 | 57 | 24 | 43 | Â | 28 | 64 | 16 | 36 | Â | |
≥ 3 | 17 | 77 | 5 | 23 |  | 10 | 48 | 11 | 52 |  | 9 | 56 | 7 | 44 |  | |
HER2 | Positive | 18 | 62 | 11 | 38 | 0.004 | 16 | 59 | 11 | 41 | 0.294 | 10 | 71 | 4 | 29 | 0.676 |
Negative | 220 | 84 | 42 | 16 | Â | 177 | 69 | 79 | 31 | Â | 155 | 76 | 48 | 24 | Â | |
Chemotherapy | None | 159 | 85 | 27 | 15 | 0.140 | 128 | 72 | 50 | 28 | 0.455 | 115 | 80 | 29 | 20 | 0.416 |
Taxane | 123 | 79 | 32 | 21 | Â | 100 | 68 | 48 | 32 | Â | 83 | 75 | 27 | 25 | Â | |
Other | 8 | 100 | 0 | 0 | Â | 5 | 56 | 4 | 44 | Â | 5 | 63 | 3 | 38 | Â | |
Trastuzumab | No | 274 | 85 | 49 | 15 | 0.005 | 218 | 70 | 92 | 30 | 0.281 | 194 | 78 | 55 | 22 | 0.497 |
Yes | 16 | 61 | 10 | 39 | Â | 15 | 60 | 10 | 40 | Â | 9 | 69 | 4 | 31 | Â | |
Taxane+trastuzumab | None/other chemo only | 166 | 86 | 26 | 14 | 0.012 | 132 | 71 | 53 | 29 | 0.558 | 120 | 79 | 31 | 21 | 0.667 |
Either | 109 | 82 | 24 | 18 | Â | 87 | 68 | 40 | 32 | Â | 74 | 75 | 25 | 25 | Â | |
Both | 15 | 62 | 9 | 38 | Â | 14 | 61 | 9 | 39 | Â | 9 | 75 | 3 | 25 | Â | |
Axillary surgery | None/SLNB | 205 | 86 | 33 | 14 | 0.027 | 163 | 72 | 63 | 28 | 0.141 | 145 | 78 | 40 | 22 | 0.590 |
ALND | 85 | 77 | 26 | 23 | Â | 70 | 64 | 39 | 36 | Â | 58 | 75 | 19 | 25 | Â | |
RT fractionation | Conventional | 240 | 82 | 52 | 18 | 0.309 | 190 | 67 | 94 | 33 | 0.013 | 165 | 75 | 55 | 25 | 0.028 |
Hypo | 50 | 88 | 7 | 12 | Â | 43 | 84 | 8 | 16 | Â | 38 | 90 | 4 | 10 | Â | |
Total RT dose (Gy) | < 60 | 92 | 89 | 11 | 11 | 0.045 | 74 | 80 | 19 | 20 | 0.014 | 66 | 84 | 13 | 16 | 0.123 |
≥ 60 | 198 | 80 | 48 | 20 |  | 159 | 66 | 83 | 34 |  | 137 | 75 | 46 | 25 |  | |
Pre-RT CRP (mg/L) | < 10 | 256 | 85 | 45 | 15 | 0.006 | 210 | 73 | 79 | 27 | 0.001 | 183 | 79 | 48 | 21 | 0.056 |
≥ 10 | 30 | 68 | 14 | 32 |  | 20 | 48 | 22 | 52 |  | 17 | 63 | 10 | 37 |  | |
Post-RT CRP (mg/L) | < 10 | 234 | 83 | 47 | 17 | 0.410 | 203 | 71 | 82 | 29 | 0.077 | 175 | 78 | 49 | 22 | 0.373 |
≥ 10 | 32 | 78 | 9 | 22 |  | 23 | 58 | 17 | 43 |  | 22 | 71 | 9 | 29 |  | |
RT-related CRP change (mg/L) | ≤ 1 | 192 | 82 | 41 | 18 | 0.992 | 170 | 72 | 67 | 28 | 0.140 | 151 | 82 | 34 | 18 | 0.006 |
> 1 | 70 | 82 | 15 | 18 |  | 53 | 63 | 31 | 37 |  | 43 | 65 | 23 | 35 |  |